Search

MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.

… Wednesday, February 22, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, published in Nature on February 22, uncover facets

On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.

… Thursday, December 18, 2025 On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators,

Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.

… Wednesday, November 13, 2024 Advances in cancer detection have saved many lives, but they have a serious drawback: Some cancers are being overdiagnosed, which can lead to the unnecessary treatment of tumors that would have posed no threat if left alone.  One cancer that may not need treatment right away

Obtenga información sobre el programa de observación activa de MSK para el cáncer de tiroides papilar, que permite a muchas personas evitar cirugías innecesarias y los riesgos que estas tienen.

… Wednesday, November 13, 2024 Los avances en la detección del cáncer han salvado muchas vidas, pero tienen una desventaja importante: algunos casos de cáncer se están sobrediagnosticando, lo que puede llevar a tratar innecesariamente tumores que no habrían representado una amenaza si se hubieran dejado

Though questions remain about how best to use genetic testing for cancer, the trend is toward more inclusive criteria.

… Tuesday, October 22, 2019 Summary Clinical genetics experts see value in testing more women for BRCA mutations. These days, anyone with an interest and about $100 can spit into a tube, mail it to a genetic testing company, and get back details on their DNA. This is known to some as recreational genomics

Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.

… Thursday, October 8, 2015 Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which

Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.

… Thursday, January 14, 2021 Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival (OS) in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease (GVHD), according to our research published recently

MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.

… Friday, January 17, 2025 When Aaron von Freter learned he had  chronic myeloid leukemia (CML) , he “felt like the room was spinning,” he remembers. “I thought I’d been served a death sentence.” Aaron was 45 years old and had no symptoms. His CML diagnosis came after standard bloodwork revealed an extremely

Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.

… Monday, October 10, 2011 Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman and CEO of Kaplan, Inc., which

Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.

… Wednesday, April 16, 2014 Summary Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution . Paul Marks — who served as President and Chief Executive Officer